REFILE-Lilly’s acute migraine drug succeeds in late-stage study

Aug 4 (Reuters) – Eli Lilly and Co said on Fridayits acute migraine drug, lasmiditan, induced a statisticallysignificant improvement in pain relief against a placebo in alate-stage study.
The post REFILE-Lilly’s acute migraine drug succeeds in late-stage study appeared first on RocketNews | Top News Stories From Around the Globe.